IP Library Granted Patent US 9,415,026
Granted Patent B2
US 9,415,026 · App. 12/945,813 · Granted Aug 16, 2016

Use of anti-bacterial agents for the treatment of epithelial-related conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,415,026
App. No.
12/945,813
Granted
Aug 16, 2016
Kind
B2
Abstract

Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.

Claims (17)

1. A method comprising steps of:

administering an anti-bacterial agent to a subject suffering from acne vulgaris caused or aggravated by Propionibacterium acnes , said anti-bacterial agent comprising an effective amount of a compound represented by the formula:

or a pharmaceutically acceptable salt thereof;

wherein the effective amount of the compound exhibits an anti-bacterial activity, which results in an IC50 against Propionibacterium acnes of between 0.5 μg/mL and about 300 μg/mL.

2. The method according to claim 1 , wherein administration is topical.

3. The method according to claim 1 , wherein administration is by inhalation.

4. The method according to claim 1 , wherein administration is parenteral.

5. A method comprising steps of:

inhibiting Propionibacterium acnes growth on a surface of an animal or Propionibacterium acnes decolonization on a surface of an animal comprising administering to a surface of the animal an effective amount of an anti-bacterial agent comprising a compound represented by the formula:

or a pharmaceutically acceptable composition thereof;

wherein the effective amount of the compound results in an IC50 against Propionibacterium acnes of about 0.5 μg/mL to about 300 μg/mL.

6. The method of claim 1 , wherein the effective amount is about 10 μg/kg to about 50 mg/kg.

7. The method of claim 1 , wherein the effective amount is about 0.2 mg/20 uL to about 0.8 mg/20 uL.

8. A method comprising steps of:

administering a topical acne composition to a subject suffering from acne vulgaris caused or aggravated by Propionibacterium acnes , wherein said composition comprises an effective amount of a compound represented by the formula:

or a pharmaceutically acceptable salt thereof, the compound exhibits both anti-bacterial activity and anti-inflammatory activity and

wherein the effective amount of the compound exhibits an anti-bacterial activity, which results in an IC50 against Propionibacterium acnes of between 0.5 μg/mL and about 300 μg/mL.

Assignments (1)
LICENSE Recorded May 7, 2012
From: SIGNUM BIOSCIENCES, INC.
To: ARGYLE THERAPEUTICS, INC.
Reel/Frame 028167/0565 →